FGF23 neutralization improves bone quality and osseointegration of titanium implants in chronic kidney disease mice

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Sun, Ningyuan ^a   Guo, Yuchen ^a   Liu, Weiqing ^a   Densmore, Michael ^b   Shalhoub, Victoria ^c,e   Erben, Reinhold G ^d   Ye, Ling ^a   Lanske, Beate ^b   Yuan, Quan ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^c AMGEN INC   (United States)

^d UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^e Siemens Healthcare Diagnostics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; NEUTRALIZING ANTIBODY; TITANIUM;

ANIMAL; ANTAGONISTS AND INHIBITORS; BONE REGENERATION; CHRONIC KIDNEY FAILURE; DRUG EFFECTS; FEMALE; IMPLANT; METABOLISM; MOUSE; PATHOLOGY; TIBIA;

ANIMALS; ANTIBODIES, NEUTRALIZING; FEMALE; FIBROBLAST GROWTH FACTORS; IMPLANTS, EXPERIMENTAL; MICE; OSSEOINTEGRATION; RENAL INSUFFICIENCY, CHRONIC; TIBIA; TITANIUM;

EID: 84954349874     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08304     Document Type: Article

References (48)

1. Al Rukhaimi, M. et al. Adaptation and Implementation of the" Kidney Disease: Improving Global Outcomes (KDIGO)" Guidelines for Evaluation and Management of Mineral and Bone Disorders in Chronic Kidney Disease for Practice in the Middle East Countries. Saudi Journal of Kidney Diseases and Transplantation 25, 133 (2014).
2. Zhang, L. et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. The Lancet 379, 815-822 (2012).
3. Anand, S. et al. High prevalence of chronic kidney disease in a community survey of urban Bangladeshis: a cross-sectional study. Globalization and health 10, 9 (2014).
4. Coresh, J. et al. Prevalence of chronic kidney disease in the United States. Jama 298, 2038-2047 (2007).
5. Hallan, S. I. et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 17, 2275-2284, doi:10.1681/ASN.2005121273 (2006).
6. Kidney Disease: Improving Global Outcomes, C. K. D. M. B. D. W. G. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney international. Supplement, S1-130, doi:10.1038/ki.2009.188 (2009).
7. Nickolas, T. L. et al. Bone mass and microarchitecture in CKD patients with fracture. Journal of the American Society of Nephrology 21, 1371-1380 (2010).
8. Lobao, R. et al. High prevalence of low bone mineral density in pre-dialysis chronic kidney disease patients: bone histomorphometric analysis. Clinical nephrology 62, 432-439 (2004).
9. Zou, H. et al. Effect of chronic kidney disease on the healing of titanium implants. Bone 56, 410-415, doi:10.1016/j.bone.2013.07.014 (2013).
10. Yoshiko, Y. et al. Mineralized tissue cells are a principal source of FGF23. Bone 40, 1565-1573 (2007).
11. Mirams, M., Robinson, B. G., Mason, R. S. & Nelson, A. E. Bone as a source of FGF23: regulation by phosphate? Bone 35, 1192-1199 (2004).
12. Huang, X., Jiang, Y. & Xia, W. FGF23 and Phosphate Wasting Disorders. Bone Research 56, 120-132 (2013).
13. White, K. E. et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nature genetics 26, 345-348 (2000).
14. Goji, K., Ozaki, K., Sadewa, A. H., Nishio, H. &Matsuo, M. Somatic and germline mosaicism for amutation of the PHEX gene can lead to genetic transmission of Xlinked hypophosphatemic rickets that mimics an autosomal dominant trait. Journal of Clinical Endocrinology & Metabolism 91, 365-370 (2006).
15. Wang, H. et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrixmineralization in vitro. J BoneMiner Res 23, 939-948, doi:10.1359/jbmr.080220 (2008).
16. Shalhoub, V. et al. Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3. E1 cell proliferation and inhibit mineralization. Calcified tissue international 89, 140-150 (2011).
17. Larsson, T., Nisbeth, U., Ljunggren,Ö., Jüppner, H. & Jonsson, K. B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney international 64, 2272-2279 (2003).
18. Hasegawa, H. et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney international 78, 975-980 (2010).
19. Mirza, M. A., Larsson, A., Lind, L. & Larsson, T. E. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 205, 385-390, doi:10.1016/j.atherosclerosis.2009.01.001 (2009).
20. Abraham, B. P., Prasad, P. & Malaty, H. M. Vitamin D deficiency and corticosteroid use are risk factors for low bone mineral density in inflammatory bowel disease patients. Digestive diseases and sciences 59, 1878-1884, doi:10.1007/s10620-014-3102-x (2014).
21. Gutierrez, O. et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. Journal of the American Society of Nephrology: JASN 16, 2205-2215, doi:10.1681/ASN.2005010052 (2005).
22. Portillo, M. R., López, I., Juan,M., Tejero, E. A. & Almaden, Y. FGF23 and mineral metabolism, implications in CKD-MBD. Nefrología: publicación oficial de la Sociedad Española de Nefrología 32, 275-278 (2012).
23. Seiler, S., Heine, G. H. & Fliser, D. Clinical relevance of FGF-23 in chronic kidney disease. Kidney International 76, S34-S42 (2009).
24. Shalhoub, V. et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. The Journal of clinical investigation 122, 2543 (2012).
25. Yuan, Q. et al. Increased osteopontin contributes to inhibition of bone mineralization in FGF23-deficient mice. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 29, 693-704, doi:10.1002/jbmr.2079 (2014).
26. Erben, R. G. et al. Overexpression of Human PHEX Under the Human b-Actin Promoter Does Not Fully Rescue the HypMouse Phenotype. Journal of Bone and Mineral Research 20, 1149-1160 (2005).
27. Dempster, D. W. et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. Journal of Bone and Mineral Research 28, 2-17 (2013).
28. Holick, M. F. Vitamin D deficiency. The New England journal of medicine 357, 266-281, doi:10.1056/NEJMra070553 (2007).
29. Pilz, S., Iodice, S., Zittermann, A.,Grant, W. B. &Gandini, S. VitaminDstatus and mortality risk in CKD: ameta-analysis of prospective studies. American Journal of Kidney Diseases 58, 374-382 (2011).
30. Jacob, A. I., Sallman, A., Santiz, Z. & Hollis, B. W. Defective photoproduction of cholecalciferol in normal and uremic humans. The Journal of nutrition 114, 1313-1319 (1984).
31. Doorenbos, C. R., van den Born, J., Navis, G. & de Borst, M. H. Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism. Nature reviews. Nephrology 5, 691-700, doi:10.1038/nrneph.2009.185 (2009).
32. Holick, M. F. Vitamin D and bone health. The Journal of nutrition 126, 1159S-1164S (1996).
33. Lips, P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocrine reviews 22, 477-501 (2001).
34. Eisman, J. A. & Bouillon, R. Vitamin D: direct effects of vitamin D metabolites on bone: lessons from genetically modified mice. BoneKEy reports 3, 499, doi:10.1038/bonekey.2013.233 (2014).
35. Liu, W. et al. Vitamin d supplementation enhances the fixation of titanium implants in chronic kidney disease mice. PloS one 9, e95689, doi:10.1371/journal.pone.0095689 (2014).
36. Raisz, L. G. Bone resorption in tissue culture. Factors influencing the response to parathyroid hormone. Journal of Clinical Investigation 44, 103 (1965).
37. Tamagaki, K. et al. Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia. Nephrology Dialysis Transplantation 21, 651-659 (2006).
38. Tam, C. S., Heersche, J. N.,Murray, T. M. & Parsons, J. A. Parathyroid Hormone Stimulates the Bone Apposition Rate Independently of Its Resorptive Action: Differential Effects of Intermittent and Continuous Administration∗. Endocrinology 110, 506-512 (1982).
39. Selby, P. L., Davies, M., Adams, J. E. & Mawer, E. B. Bone loss in celiac disease is related to secondary hyperparathyroidism. Journal of Bone and Mineral Research 14, 652-657 (1999).
40. Silver, J. & Naveh-Many, T. FGF-23 and secondary hyperparathyroidism in chronic kidney disease. Nature reviews. Nephrology 9, 641-649, doi:10.1038/nrneph.2013.147 (2013).
41. Bergwitz, C. & Jüppner, H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annual review of medicine 61, 91-104 (2010).
42. Moe, O. W. Fibroblast growth factor 23: friend or foe in uremia? The Journal of clinical investigation 122, 2354 (2012).
43. Rangiani, A. et al. Dentin matrix protein 1 and phosphate homeostasis are critical for postnatal pulp, dentin and enamel formation. International journal of oral science 4, 189-195, doi:10.1038/ijos.2012.69 (2012).
44. London, G. M. et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrology Dialysis Transplantation 18, 1731-1740 (2003).
45. Nitta, K. et al. Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients. Hypertension research: official journal of the Japanese Society of Hypertension 27, 47-52 (2004).
46. Raggi, P. et al. Cardiac calcification in adult hemodialysis patientsA link between end-stage renal disease and cardiovascular disease? Journal of the American College of Cardiology 39, 695-701 (2002).
47. Carpenter, T. O. et al. Randomized trial of the anti-FGF23 antibody KRN23 in Xlinked hypophosphatemia. The Journal of clinical investigation 124, 1587 (2014).
48. Huang, X., Lindholm, B., Stenvinkel, P. & Carrero, J. J. Dietary fat modification in patients with chronic kidney disease: n-3 fatty acids and beyond. Journal of nephrology 26, 960 (2013).